vs
汉瑞祥（HSIC）与拉夫劳伦（RL）财务数据对比。点击上方公司名可切换其他公司
汉瑞祥的季度营收约是拉夫劳伦的1.4倍（$3.4B vs $2.4B），拉夫劳伦净利率更高（15.0% vs 2.9%，领先12.1%），拉夫劳伦同比增速更快（12.2% vs 7.7%），拉夫劳伦自由现金流更多（$704.0M vs $338.0M），过去两年拉夫劳伦的营收复合增速更高（23.9% vs 4.1%）
汉瑞祥（Henry Schein, Inc.）是美国的医疗保健产品及服务分销商，业务覆盖全球33个国家和地区，是全球面向诊所类牙科及医疗从业者的最大医疗解决方案供应商。公司连续14年入选Ethisphere评选的「全球最具道德企业」榜单，2025年再次登榜。
拉夫劳伦是源自美国的跨国时尚巨头，旗下同名高端时尚品牌风靡全球，企业规模达数十亿美元。品牌创始人拉夫劳伦于2015年9月卸任首席执行官，仍留任执行董事长兼首席创意官，主导品牌创意与整体发展方向。
HSIC vs RL — 直观对比
营收规模更大
HSIC
是对方的1.4倍
$2.4B
营收增速更快
RL
高出4.5%
7.7%
净利率更高
RL
高出12.1%
2.9%
自由现金流更多
RL
多$366.0M
$338.0M
两年增速更快
RL
近两年复合增速
4.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.4B | $2.4B |
| 净利润 | $101.0M | $361.6M |
| 毛利率 | 30.9% | 69.9% |
| 营业利润率 | 4.7% | 19.6% |
| 净利率 | 2.9% | 15.0% |
| 营收同比 | 7.7% | 12.2% |
| 净利润同比 | 7.4% | 21.6% |
| 每股收益（稀释后） | $0.85 | $5.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HSICRL
| Q4 25 | $3.4B | $2.4B | ||
| Q3 25 | $3.3B | $2.0B | ||
| Q2 25 | $3.2B | $1.7B | ||
| Q1 25 | $3.2B | $1.7B | ||
| Q4 24 | $3.2B | $2.1B | ||
| Q3 24 | $3.2B | $1.7B | ||
| Q2 24 | $3.1B | $1.5B | ||
| Q1 24 | $3.2B | $1.6B |
净利润HSICRL
| Q4 25 | $101.0M | $361.6M | ||
| Q3 25 | $101.0M | $207.5M | ||
| Q2 25 | $86.0M | $220.4M | ||
| Q1 25 | $110.0M | $129.0M | ||
| Q4 24 | $94.0M | $297.4M | ||
| Q3 24 | $99.0M | $147.9M | ||
| Q2 24 | $104.0M | $168.6M | ||
| Q1 24 | $93.0M | $90.7M |
毛利率HSICRL
| Q4 25 | 30.9% | 69.9% | ||
| Q3 25 | 30.7% | 68.0% | ||
| Q2 25 | 31.4% | 72.3% | ||
| Q1 25 | 31.6% | 68.7% | ||
| Q4 24 | 31.1% | 68.4% | ||
| Q3 24 | 31.3% | 67.0% | ||
| Q2 24 | 32.5% | 70.5% | ||
| Q1 24 | 31.9% | 66.6% |
营业利润率HSICRL
| Q4 25 | 4.7% | 19.6% | ||
| Q3 25 | 4.9% | 12.2% | ||
| Q2 25 | 4.7% | 15.9% | ||
| Q1 25 | 5.5% | 9.1% | ||
| Q4 24 | 4.9% | 18.2% | ||
| Q3 24 | 4.9% | 10.4% | ||
| Q2 24 | 5.1% | 13.8% | ||
| Q1 24 | 4.7% | 6.9% |
净利率HSICRL
| Q4 25 | 2.9% | 15.0% | ||
| Q3 25 | 3.0% | 10.3% | ||
| Q2 25 | 2.7% | 12.8% | ||
| Q1 25 | 3.5% | 7.6% | ||
| Q4 24 | 2.9% | 13.9% | ||
| Q3 24 | 3.1% | 8.6% | ||
| Q2 24 | 3.3% | 11.1% | ||
| Q1 24 | 2.9% | 5.8% |
每股收益（稀释后）HSICRL
| Q4 25 | $0.85 | $5.82 | ||
| Q3 25 | $0.84 | $3.32 | ||
| Q2 25 | $0.70 | $3.52 | ||
| Q1 25 | $0.88 | $2.03 | ||
| Q4 24 | $0.75 | $4.66 | ||
| Q3 24 | $0.78 | $2.31 | ||
| Q2 24 | $0.80 | $2.61 | ||
| Q1 24 | $0.72 | $1.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $156.0M | $2.3B |
| 总债务越低越好 | $2.3B | — |
| 股东权益账面价值 | $3.2B | $2.9B |
| 总资产 | $11.2B | $7.8B |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资HSICRL
| Q4 25 | $156.0M | $2.3B | ||
| Q3 25 | $136.0M | $1.6B | ||
| Q2 25 | $145.0M | $2.3B | ||
| Q1 25 | $127.0M | $2.1B | ||
| Q4 24 | $122.0M | $2.1B | ||
| Q3 24 | $126.0M | $1.7B | ||
| Q2 24 | $138.0M | $1.8B | ||
| Q1 24 | $159.0M | $1.8B |
总债务HSICRL
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | $2.0B | — |
股东权益HSICRL
| Q4 25 | $3.2B | $2.9B | ||
| Q3 25 | $3.4B | $2.6B | ||
| Q2 25 | $3.4B | $2.5B | ||
| Q1 25 | $3.3B | $2.6B | ||
| Q4 24 | $3.4B | $2.5B | ||
| Q3 24 | $3.5B | $2.4B | ||
| Q2 24 | $3.5B | $2.4B | ||
| Q1 24 | $3.6B | $2.5B |
总资产HSICRL
| Q4 25 | $11.2B | $7.8B | ||
| Q3 25 | $11.1B | $7.3B | ||
| Q2 25 | $10.9B | $7.8B | ||
| Q1 25 | $10.5B | $7.0B | ||
| Q4 24 | $10.2B | $7.1B | ||
| Q3 24 | $10.6B | $6.8B | ||
| Q2 24 | $10.3B | $6.6B | ||
| Q1 24 | $10.1B | $6.6B |
负债/权益比HSICRL
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.64× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.59× | — | ||
| Q4 24 | 0.54× | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 0.56× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $381.0M | $779.6M |
| 自由现金流经营现金流 - 资本支出 | $338.0M | $704.0M |
| 自由现金流率自由现金流/营收 | 9.8% | 29.3% |
| 资本支出强度资本支出/营收 | 1.3% | 3.1% |
| 现金转化率经营现金流/净利润 | 3.77× | 2.16× |
| 过去12个月自由现金流最近4个季度 | $573.0M | $694.5M |
8季度趋势，按日历期对齐
经营现金流HSICRL
| Q4 25 | $381.0M | $779.6M | ||
| Q3 25 | $174.0M | $53.2M | ||
| Q2 25 | $120.0M | $176.1M | ||
| Q1 25 | $37.0M | $122.2M | ||
| Q4 24 | $204.0M | $738.4M | ||
| Q3 24 | $151.0M | $97.2M | ||
| Q2 24 | $296.0M | $277.3M | ||
| Q1 24 | $197.0M | — |
自由现金流HSICRL
| Q4 25 | $338.0M | $704.0M | ||
| Q3 25 | $141.0M | $-40.6M | ||
| Q2 25 | $88.0M | $-11.2M | ||
| Q1 25 | $6.0M | $42.3M | ||
| Q4 24 | $168.0M | $677.2M | ||
| Q3 24 | $117.0M | $55.5M | ||
| Q2 24 | $259.0M | $243.9M | ||
| Q1 24 | $156.0M | — |
自由现金流率HSICRL
| Q4 25 | 9.8% | 29.3% | ||
| Q3 25 | 4.2% | -2.0% | ||
| Q2 25 | 2.7% | -0.7% | ||
| Q1 25 | 0.2% | 2.5% | ||
| Q4 24 | 5.3% | 31.6% | ||
| Q3 24 | 3.7% | 3.2% | ||
| Q2 24 | 8.3% | 16.1% | ||
| Q1 24 | 4.9% | — |
资本支出强度HSICRL
| Q4 25 | 1.3% | 3.1% | ||
| Q3 25 | 1.0% | 4.7% | ||
| Q2 25 | 1.0% | 10.9% | ||
| Q1 25 | 1.0% | 4.7% | ||
| Q4 24 | 1.1% | 2.9% | ||
| Q3 24 | 1.1% | 2.4% | ||
| Q2 24 | 1.2% | 2.2% | ||
| Q1 24 | 1.3% | — |
现金转化率HSICRL
| Q4 25 | 3.77× | 2.16× | ||
| Q3 25 | 1.72× | 0.26× | ||
| Q2 25 | 1.40× | 0.80× | ||
| Q1 25 | 0.34× | 0.95× | ||
| Q4 24 | 2.17× | 2.48× | ||
| Q3 24 | 1.53× | 0.66× | ||
| Q2 24 | 2.85× | 1.64× | ||
| Q1 24 | 2.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HSIC
| Global Dental Merchandise | $1.2B | 35% |
| Global Medical | $1.1B | 31% |
| Global Dental Equipment | $536.0M | 16% |
| Global Specialty Products | $422.0M | 12% |
| Global Technology | $173.0M | 5% |
| Global Value Added Services | $64.0M | 2% |
| Equity Method Investee | $14.0M | 0% |
RL
暂无分部数据
